PLASMA CELL MYELOMA

This study tested whether adding two drugs (ixazomib and dexamethasone) to the standard maintenance drug lenalidomide could better control multiple myeloma that remains after a stem cell transplant. 42 adults who had already started lenalidomide maintenance were randomly assigned…

This study tested whether adding the drug isatuximab to a standard two-drug therapy (carfilzomib and dexamethasone) helps people with multiple myeloma that has come back or stopped responding to treatment. About 300 adults who had already tried 1 to 3 prior treatments took part. …

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by a stem cell transplant. The goal w…

This study looked at whether people with multiple myeloma or non-Hodgkin lymphoma who get a stem cell transplant can safely skip a drug called tbo-filgrastim (G-CSF) after the transplant. The drug is normally used to help white blood cells recover faster. The goal was to see if s…

This early-stage study tested a new drug called SAR442085 in 37 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find the safest dose and check for any signs that the drug shrinks tumors. Researchers also monitored s…

This study looked at 56 older adults (65+) with multiple myeloma to see if a comprehensive geriatric assessment—a series of questions and tests about physical and mental health—along with blood tests could predict who would have severe side effects from chemotherapy. The goal is …